Conclusions: Against a backdrop of supportive public funding of ART in Australia, a voluntary shift to single embryo transfer by fertility clinicians and ART patients has resulted in substantial savings in hospital costs. Much of the growth in ART use has been theoretically cross-subsidised by the move to safer embryo transfer practices.
1 At current levels of ART activity in Australia, 3.3% of children, or almost one child in every Australian classroom, is born as a result of ART treatment. 2 Arguably, the greatest challenge facing ART treatment worldwide is the high rate of twin and triplet births resulting from the transfer of multiple embryos. Multiple births are associated with significantly increased risks for both mothers and babies, including pregnancy and delivery complications, preterm birth, long-term disability, and death.
3-5 Australia has been a world leader in reducing the incidence of ART multiple births through a voluntary shift to single embryo transfer (SET).
This reduction in the number of embryos transferred in Australia has occurred against a backdrop of supportive public funding of ART over the past decade, through the Medicare Benefits Schedule (MBS) and the Pharmaceutical Benefits Scheme (PBS). Since 2000, couples have been eligible for partial reimbursement of an unlimited number of ART cycles without restrictions on parental age or numbers of previous treatment attempts or existing children. The most significant change to funding of ART in the past decade was the introduction of the Extended Medicare Safety Net (EMSN) in 2004, which reimburses 80% of out-of-pocket expenses for out-of-hospital Medicare services once an annual threshold is reached. This policy effectively reduced out-of-pocket expenses for ART patients to about 20% of the cost of an ART cycle. 6, 7 We aimed to calculate the cost savings to Australian federal and state governments from the reduction in ART multiple births since 2002, and to determine the theoretical number of ART treatments publicly funded through these savings.
Methods
Data sources for costing model 
Hospital birth-admission costs
The costs of caring for mothers and their babies born as a result of ART treatment were sourced from a previously published study on the inpatient birth-admission costs of ART births in Australia in 2003. 8 The hospital costs were limited to the cost of the initial birth admission, defined as the inpatient admission for a birth event until the first separation.
We made several adjustments to the hospital admission costs to reflect only the contribution of government funding. First, data from the Australian Institute of Health and Welfare National Perinatal Data Collection were used to stratify singleton, twin and triplet birth admissions, based on hospital sector and elected accommodation status, into i) publicly funded patients, ii) privately funded patients in public hospitals, and iii) privately funded patients in private hospitals. Second, the weighted average birthadmission costs of the latter two patient categories were adjusted by 40% and 35% of the cost, respectively, to reflect the government contribution to funding. 9 The resulting weighted average maternal and infant birth-admission costs from a government perspective in the 2003-04 financial year were $6295 for singleton births, $17 058 for twin births and $75 921 for triplet births. These costs were indexed to the year in which they were incurred using the Consumer Price Index "health" group.
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Government costs of ART treatment
Data from Medicare Australia (http:// www.medicareaustralia.gov.au/provider/medicare/mbs.jsp) on annual service counts and benefits paid for MBS items 13200 (ART service), 13209 (planning and management of ART treatment), 13212 (oocyte retrieval), 13215 (fresh embryo transfer), 13218 (frozen/thawed embryo transfer cycle), 13221 (semen preparation) and 13251 (intracytoplasmic sperm injection) were used to calculate the average Medicare benefits for one ART treatment program (comprising one fresh embryo transfer cycle plus one frozen/thawed embryo transfer cycle). These benefits included those paid through the EMSN. With the addition of the estimated cost of PBS drugs used during treatment, the average cost to Medicare for one treatment program The number of ART treatment programs that were theoretically funded by the savings in birth-admission costs was computed by dividing the total savings in hospital costs by the cost to Medicare (MBS and PBS) of one ART treatment program. Finally, the theoretical number of infants born by ART from these savings was calculated by applying annual treatment success rates and multiple birth rates for the year in which the savings were incurred. From the perspective of government accounts, dividing the cost savings in each year by the average MBS and PBS benefits for one ART program theoretically funded 7042 ART programs comprising one fresh plus one frozen embryo transfer cycle. 
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The savings identified here were based only on the initial birth admission and therefore significantly underestimate the long-term health care costs associated with caring for multiple birth infants. Even after the initial birth admission, twins and triplets are 3.9 and 10.6 times more likely, respectively, to be transferred to another hospital than singleton infants. 8 Therefore, it is likely that even the average cost of the birth episode has been underestimated in our study. Multiple births also continue to generate higher long-term medical, education and social services costs than singleton births. [13] [14] [15] Percentage of increased ART use overall funded through savings 55% MBS = Medicare Benefits Schedule. PBS = Pharmaceutical Benefits Scheme. * A live-birth delivery is defined as the birth of at least one live-born infant of у 20 weeks' gestation or у 400 g in birthweight. † The ART multiple birth rate was calculated as the number of live-birth deliveries with more than one infant divided by the total number of live-birth deliveries, based on ART cycles where embryos were transferred. ‡ Government savings in birth-admission costs = (estimated cost of adjusted number of live-birth deliveries following embryo transfer ART cycles, assuming 2002 multiple delivery rate)  (cost of observed live-birth deliveries following embryo transfer ART cycles). § For the purposes of this study, an ART program comprised one fresh plus one frozen/thawed embryo transfer cycle. ¶ Theoretical number of ART programs funded = (government savings in birth-admission costs)  (estimated average MBS and PBS benefits for one ART program). ** Sourced from the Australia and New Zealand Assisted Reproduction Database. † † Numbers of infants were based on the observed proportion of singleton, twin and triplet infants resulting from ART treatment undertaken in each year. Assumes that all infants in a live-birth delivery are born alive (eg, both twin infants born alive). ◆ has persuaded several jurisdictions, such as Belgium, Sweden and Quebec, to provide public funding for ART, thereby encouraging safer embryo transfer practices and leading to reduced multiple birth rates. [16] [17] [18] A limitation of this study was the accuracy of the assumptions used to adjust the birth-admission costs to reflect the public contribution to funding. The birth-admission costs were estimated from a previous study using Australian Government national public hospital cost weights, and adjustments were based on reported funding allocations for women giving birth in Australian hospitals. However, given the complex funding allocations for admitted patients in Australia, the assumptions used would have some level of uncertainty.
The reduction in multiple births has primarily occurred as a result of a voluntary shift to use of SET. The Fertility Society of Australia Reproductive Technology Accreditation Committee's code of practice requires fertility clinics to limit the numbers of embryos that should be transferred, 19 but there is no legislation enforcing these guidelines. Similarly, the number of embryos transferred is not linked to government funding, which is a model adopted by some countries to reduce multiple birth rates. 20 There is still significant variation in the uptake of SET around the world. With a SET rate of 67.7% and an ART multiple birth rate of 8.6% in 2008, Australia is a world leader in safe embryo transfer practices. By comparison, the United Kingdom and United States report SET rates for fresh embryo transfer cycles of only 11.6% in each country and multiple birth rates of 23.1% and 31.4%, respectively. The difference in the proportion of fresh embryo transfer cycles with three or more embryos transferred is also striking, with rates of 40.4% in the US and 4.8% in the UK, compared with 0.6% in Australia. 21, 22 The reasons for differences in embryo transfer practices between countries are multifactorial. However, studies from the US and Europe consistently show that higher financial support of ART, either through public or private insurance, is associated with low numbers of embryos transferred during treatment and thus lower multiple birth rates. [23] [24] [25] [26] [27] Where treatment is unaffordable -through high treatment costs and/or lack of government subsidisation -there is a financial incentive for ART patients to achieve pregnancy in a limited number of cycles. In the US in 2006, one standard fresh IVF cycle equated to 44% of an individual's annual disposable income, compared with 25% in the UK and 6% in Australia.
7 While these variations exert pressure on both ART patients and fertility specialists to transfer two or more embryos in one cycle, one fresh SET cycle followed by one frozen/thawed SET cycle provides live-birth rates comparable to those associated with double embryo transfer. 28 Despite the health risks involved for both mothers and babies, a substantial proportion of couples desire multiple births as an outcome of ART treatment. 29, 30 It is therefore important that policymakers are aware of how changes to ART funding affect access to treatment and clinical practice, and ultimately the health of children born following ART. Although it is the couple who undergo ART treatment in their desire to have a child, it is the children who are most at risk of the adverse sequelae associated with multiple gestation pregnancy. Clearly, it is also false economy to restrict funding for ART, which only accounts for 0.25% of health care expenditure in Australia, 6,7 if it results in higher downstream costs of caring for multiple birth children. In Australia, the EMSN was revised in January 2010 to cap benefits paid to patients for selected Medicare items, including all ART services. The impact of this change on SET and multiple birth rates is yet to be seen.
In conclusion, funding arrangements for ART not only affect who can afford to access ART treatment, but also have the potential to alter the health outcomes of children born as a result. For the sake of the health of children born following ART, we should be asking: "Can we afford not to fund it?"
